Dobutamine pharmacokinetics during dobutamine stress echocardiography

American Journal of Cardiology

Volumn 79, Issue 10, 1997, Pages 1381-1386

  Daly, Annemarie L ^a   Linares, Oscar A ^a   Smith, Maria J ^a   Starling, Mark R ^a   Supiano, Mark A ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONOTROPISM; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; AGED; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; HEART RATE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; STROKE VOLUME;

EID: 0030977888     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00144-6     Document Type: Article

References (27)

1. Pellikka PA, Roger VL, Oh JK, Miller FA, Seward JB, Tajik AJ. Stress echocardiography. Part II. Dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 1995;70:16-27.
2. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-196.
3. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 1979;300:17-22.
4. McNeill AJ, Fioretti PM, El-Said EM, Salustri A, Forster T, Roelandt JRTC. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol 1992;70:41-46.
5. Ling LH, Pellikka PA, Mahoney DW, McCully RB, Roger VL, Seward JB. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. J Am Coll Cardiol 1996;28:551-557.
6. Santiago P, Rosamond TL. Dobutamine stress echocardiography: clinical utility and predictive value at various infusion rates. Am Heart J 1994;128:804-808.
7. Habib DM, Padbury JF, Anas NG, Perkin RM, Minegar C. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med 1992;20:601-608.
8. Banner W Jr, Vernon DD, Minton SD, Dean JM. Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med 1991;19:871-873.
9. Schwartz PH, Eldadah MK, Newth CJL. The pharmacokinetics of dobutamine in pediatric intensive care unit patients. Drug Metab Dispos 1991;19:614-618.
10. Klem C, Dasta JF, Reilley TE, Flancbaum LJ. Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients. Crit Care Med 1994;22:1926-1932.
11. Kates RE, Leier CV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978;24:537-541.
12. Berg RA, Donnerstein RL, Padbury JF. Dobutamine infusions in stable, critically ill children: pharmacokinetics and hemodynamic actions. Crit Care Med 1993;21:678-686.
13. Berg RA, Padbury JF, Donnerstein RL, Klewer SE, Hutter JJ Jr. Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents. J Pharmacol Exp Ther 1993;265:1232-1238.
14. 2, pH, and lactate from arterialized venous samples. J Appl Physiol 1972;41:565-573.
15. Dixon R, Hsiao J, and Caldwell W. Cardiotonic agents: a simple HPLC procedure for the quantification of dobutamine and a new congener in plasma. Research Communications in Chemical Pathology and Pharmacology 1985;48(2):313-316.
16. Evans MI, Halter JB, and Porte D, Jr. Comparison of double-and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clinical Chemistry 1978;24:467-570.
17. Berman MW, Weiss MF. SAAM Manual. Publication No. (NIH) 78-180. United States Department of Health, Education, and Welfare, Washington, D.C. 1978.
18. Berman MW, Beltz F, Grief PC, Chabay R, Boston RC. CONSAAM User's Guide. No. 1983-421-132:3279. United States Government Printing Office, Washington, D.C., 1984.
19. Akaike H. A new look at the statistical model identification. IEEE Trans on Automatic Control 1974:19:716-723.
20. Berman M. Iodine kinetics. In: Methods of Investigative Endocrinology. Amsterdam, Holland: North-Holland Publishing 1972:172-203.
21. Halter JB, Stratton JR, Pfeifer MA. Plasma catecholamines and hemodynamic responses to stress states in man. Acta Physiol Scand 1984;527:31-38.
22. Mertes H, Sawada SG, Ryan T, Segar DS, Kovacs R, Foltz J, Feigenbaum H. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography: experience in 1118 patients. Circulation 1993;88:15-19.
23. Lewandowski TJ, Armstrong WF, Hepner AM, Bach DS. Early identification of patients requiring atropine during dobutamine stress echocardiography reduces test time. J Invest Med 1996;44:348A.
24. Cryer PE, Rizza RA, Haymond MW, Gerich JE. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism 1980;29:1114-1118.
25. Morrow LA, Linares OA, Hill TJ, Sanfield JA, Supiano MA, Rosen SG, Halter JB. Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. J Endocrinol Metab 1987;65:508-511.
26. Supiano MA, Linares OA, Smith MJ, Halter JB. Age-related differences in norepinephrine kinetics: effect of posture and sodium-restricted diet. Am J Physiol 1990;259:E422-E431.
27. Hogikyan RV, Supiano MA. Arterial α-adrenergic responsiveness is decreased and sympathetic nervous system activity is increased in older humans. Am J Physiol 1994;266:E717-E724.